Naloxone use by non-medical bystanders on the rise, but not fast enough

Use of a lifesaving drug to reverse opioid drug overdoses is growing, but not fast enough. That’s according to new research in JAMA Network Open from The Ohio State University College of Medicine, College of Public Health and the National Registry of Emergency Medical Technicians.

Zepbound’s Weight Loss, Cardiometabolic Benefits Hold Up at 3 Years

SAN ANTONIO — Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of tirzepatide (Zepbound) and maintained

November 8, 2024

Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

The youngest candidate on Wednesday night’s debate stage didn’t make any friends among his fellow Republican presidential hopefuls, questioning their morality, mocking their promises, and

August 24, 2023

Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials

Biomea’s BMF-219 is an investigational irreversible covalent inhibitor of menin. Image credit: eamesBot / Shutterstock. Biomea Fusion’s stock is on the up after the company

September 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.